source
- Lilly ends partnership with Foghorn after lead cancer drug fails efficacy testsLilly announced it is ending its collaboration with Foghorn Therapeutics after the biotech's lead cancer candidate, FHD-909, did not meet efficacy benchmarks in testing. The decision halts the join…
- United Therapeutics wins Delaware court case; BMS secures pediatric approval for CamzyosUnited Therapeutics secured a legal victory in a federal court in Delaware, with the judge ruling in the company's favor. The decision marks a notable win for the biotech firm, though the specific…